ZYME Zymeworks Inc
Price (delayed)
$11.7
Market cap
$814.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$766.42M
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
Highlights
The company's debt fell by 31% YoY and by 9% QoQ
Zymeworks's gross profit has increased by 23% QoQ
ZYME's EPS is down by 9% since the previous quarter but it is up by 6% year-on-year
The quick ratio has dropped by 55% year-on-year and by 16% since the previous quarter
The company's equity fell by 27% YoY and by 8% QoQ
Key stats
What are the main financial stats of ZYME
Market
Valuations
Earnings
Shares outstanding
69.58M
Market cap
$814.05M
Enterprise value
$766.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.38
Price to sales (P/S)
11.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.04
Revenue
$76.3M
Gross profit
$76.3M
Operating income
-$137.11M
Net income
-$122.7M
EBIT
-$116.61M
EBITDA
-$105.42M
Free cash flow
-$112.04M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.48
Book value per share
$4.92
Revenue per share
$1.01
TBVPS
$5.89
Total assets
$463.09M
Total liabilities
$124.32M
Debt
$18.48M
Equity
$338.77M
Working capital
$212.16M
Debt to equity
0.05
Current ratio
3.4
Quick ratio
3.19
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-138.2%
Gross margin
100%
Net margin
-160.8%
Operating margin
-179.7%
Return on assets
-24.3%
Return on equity
-31.7%
Return on invested capital
-34%
Return on capital employed
-31.1%
Return on sales
-152.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYME stock price
How has the Zymeworks stock price performed over time
Intraday
5.41%
1 week
-8.24%
1 month
-11.7%
1 year
5.88%
YTD
-20.08%
QTD
-20.08%
Financial performance
How have Zymeworks's revenue and profit performed over time
Revenue
$76.3M
Gross profit
$76.3M
Operating income
-$137.11M
Net income
-$122.7M
Gross margin
100%
Net margin
-160.8%
Zymeworks's gross profit has increased by 23% QoQ
Zymeworks's revenue has increased by 23% from the previous quarter
The operating margin has increased by 19% from the previous quarter
The company's net margin rose by 12% QoQ but it fell by 3% YoY
Growth
What is Zymeworks's growth rate over time
Valuation
What is Zymeworks stock price valuation
P/E
N/A
P/B
2.38
P/S
11.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.04
ZYME's EPS is down by 9% since the previous quarter but it is up by 6% year-on-year
The company's equity fell by 27% YoY and by 8% QoQ
ZYME's P/B is 13% above its last 4 quarters average of 2.1 but 8% below its 5-year quarterly average of 2.6
The stock's price to sales (P/S) is 63% less than its 5-year quarterly average of 31.4 and 17% less than its last 4 quarters average of 14.0
Zymeworks's revenue has increased by 23% from the previous quarter
Efficiency
How efficient is Zymeworks business performance
Zymeworks's return on equity has decreased by 21% YoY and by 17% QoQ
Zymeworks's ROA has decreased by 20% YoY and by 14% from the previous quarter
ZYME's ROS is up by 19% since the previous quarter and by 2.6% year-on-year
ZYME's ROIC is down by 7% year-on-year and by 3.3% since the previous quarter
Dividends
What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZYME.
Financial health
How did Zymeworks financials performed over time
The quick ratio has dropped by 55% year-on-year and by 16% since the previous quarter
The company's current ratio has shrunk by 54% YoY and by 17% QoQ
The company's debt is 95% lower than its equity
The company's debt fell by 31% YoY and by 9% QoQ
The company's equity fell by 27% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.